David McIntosh: Vital Plasma Derived Medicines – The Anomalous UK Scene
David McIntosh, Founder and Chair of United Plasma Action, shared a post on LinkedIn:
“Vital Plasma Derived Medicines: The Anomalous UK Scene
In the context of recent news of the renewed availability of plasma from UK citizens, and former UK residents, for pharmaceutical use in vital medicines production, this reminder may be apposite.
Unlike other National Regulators, the UK Authority, the MHRA, is apparently still haunted by phantom fears of the 20th Century Mad Cow Disease – leading it to maintain its utterly unwarranted prohibition of the use of UK donors’ plasma for the manufacture of a dozen or so vital medicines for which it is a perfectly suitable raw material.
This misguided behaviour is not only enforcing a most unfortunate waste of precious components of UK donors’ plasma – and costing the NHS money in the passing – it is also exacerbating severe global shortages of many of these life-saving medicines.
We UK donors may well ask – ‘why?’
Indeed, some of us have been asking this question for some years now.
Answer comes there none …
What do other donors and fellow LinkedIners think about this ?”
Find more posts featuring David McIntosh on Hemostasis Today.
-
Sep 5, 2026, 16:28Jon Douglas: Imperial College London Review Maps Key Pathways in Autoimmune Thrombosis
-
Sep 5, 2026, 16:21Kelly Anderson: Bilateral Foot Pain and Purple Toes – Spotting Vascular Complications in Polycythemia Vera
-
Sep 5, 2026, 16:16Hazem Abosheaishaa: Beta-Blocker Selection Matters – Multi-Institutional Cohort Insights on PVT and Survival in Cirrhosis
-
Sep 5, 2026, 16:08Indre Ceponiene: Major Gaps in Secondary Cardiovascular Prevention Across Europe
-
Sep 5, 2026, 16:03W. Alberto Sifuentes Giraldo: Why Obstetric Cases Are Missed Under 2023 ACR/EULAR APS Criteria
-
Sep 5, 2026, 15:58Srikanth Nalla: A Case of Saddle Pulmonary Embolism
-
Sep 5, 2026, 15:55COPD-specific Pulmonary Embolism Diagnostic Strategy – Thrombosis and Haemostasis
-
Sep 5, 2026, 15:41Sam Tsimikas on Lp(a) HORIZON Topline Results – What Missed Endpoints Mean for Cardiovascular Risk
-
Sep 5, 2026, 15:32Stefano Garzon: SELUTION DeNovo HBR – Weren’t HBR Patients Supposed to Bleed More with DES?